Ontology highlight
ABSTRACT:
SUBMITTER: Balbino B
PROVIDER: S-EPMC7269578 | biostudies-literature | 2020 Mar
REPOSITORIES: biostudies-literature
Balbino Bianca B Herviou Pauline P Godon Ophélie O Stackowicz Julien J Goff Odile Richard-Le OR Iannascoli Bruno B Sterlin Delphine D Brûlé Sébastien S Millot Gael A GA Harris Faith M FM Voronina Vera A VA Nadeau Kari C KC Macdonald Lynn E LE Murphy Andrew J AJ Bruhns Pierre P Reber Laurent L LL
The Journal of clinical investigation 20200301 3
Omalizumab is an anti-IgE monoclonal antibody (mAb) approved for the treatment of severe asthma and chronic spontaneous urticaria. Use of omalizumab is associated with reported side effects ranging from local skin inflammation at the injection site to systemic anaphylaxis. To date, the mechanisms through which omalizumab induces adverse reactions are still unknown. Here, we demonstrated that immune complexes formed between omalizumab and IgE can induce both skin inflammation and anaphylaxis thro ...[more]